Cost-effectiveness of migraine drugs analyzed

Published: 2007-12-31 06:59:00

Updated: 2007-12-31 06:59:00

The Health Insurance Review Agency announced on December 26 the results of 11 anti-migraine agents from 41 pharmaceutical firms in terms of cost-effectiveness and clinical efficacy.

In a comprehensive analysis of the scientific data on 11 different substances to treat migraine, the HIRA found ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK